To amend title XVIII of the Social Security Act to expand coverage of the in-home administration of intravenous immune globulin under the Medicare program.

Bill 119 HR 1143, also known as the In-Home IVIG Access Act, aims to make changes to the Medicare program in order to expand coverage for the in-home administration of intravenous immune globulin (IVIG). IVIG is a treatment used for individuals with immune deficiencies or autoimmune disorders.

The bill proposes to amend Title XVIII of the Social Security Act to allow for coverage of IVIG administration in the home setting, rather than requiring patients to receive treatment in a medical facility. This change would provide greater flexibility and convenience for patients who require regular IVIG treatments.

By expanding coverage for in-home IVIG administration, the bill seeks to improve access to care for individuals who rely on this treatment to maintain their health and well-being. This could potentially lead to cost savings for both patients and the Medicare program, as in-home administration may be more cost-effective than receiving treatment in a medical facility. Overall, the In-Home IVIG Access Act aims to enhance the quality of care for individuals who require IVIG treatment, while also potentially reducing healthcare costs. The bill is currently under consideration in Congress and may have a significant impact on individuals who rely on IVIG therapy.